company background image
4151 logo

Kyowa Kirin TSE:4151 Stock Report

Last Price

JP¥2.62k

Market Cap

JP¥1.4t

7D

-0.4%

1Y

-12.5%

Updated

25 Apr, 2024

Data

Company Financials +

4151 Stock Overview

Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, marketing, and import/export of pharmaceuticals for oncology, nephrology, central nervous system, and immunology therapeutic areas in Japan, the United States, rest of the Americas, Europe, Asia, and internationally.

4151 fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance5/6
Financial Health6/6
Dividends5/6

Kyowa Kirin Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Kyowa Kirin
Historical stock prices
Current Share PriceJP¥2,624.00
52 Week HighJP¥3,075.00
52 Week LowJP¥2,266.50
Beta0.20
1 Month Change-4.22%
3 Month Change12.21%
1 Year Change-12.53%
3 Year Change-20.24%
5 Year Change21.71%
Change since IPO98.79%

Recent News & Updates

Kyowa Kirin's (TSE:4151) Dividend Will Be ¥29.00

Apr 11
Kyowa Kirin's (TSE:4151) Dividend Will Be ¥29.00

Here's Why We Think Kyowa Kirin (TSE:4151) Is Well Worth Watching

Mar 19
Here's Why We Think Kyowa Kirin (TSE:4151) Is Well Worth Watching

Kyowa Kirin Co., Ltd.'s (TSE:4151) 26% Price Boost Is Out Of Tune With Earnings

Feb 27
Kyowa Kirin Co., Ltd.'s (TSE:4151) 26% Price Boost Is Out Of Tune With Earnings

Recent updates

Kyowa Kirin's (TSE:4151) Dividend Will Be ¥29.00

Apr 11
Kyowa Kirin's (TSE:4151) Dividend Will Be ¥29.00

Here's Why We Think Kyowa Kirin (TSE:4151) Is Well Worth Watching

Mar 19
Here's Why We Think Kyowa Kirin (TSE:4151) Is Well Worth Watching

Kyowa Kirin Co., Ltd.'s (TSE:4151) 26% Price Boost Is Out Of Tune With Earnings

Feb 27
Kyowa Kirin Co., Ltd.'s (TSE:4151) 26% Price Boost Is Out Of Tune With Earnings

Shareholder Returns

4151JP PharmaceuticalsJP Market
7D-0.4%2.7%1.8%
1Y-12.5%4.7%31.0%

Return vs Industry: 4151 underperformed the JP Pharmaceuticals industry which returned 4.7% over the past year.

Return vs Market: 4151 underperformed the JP Market which returned 31% over the past year.

Price Volatility

Is 4151's price volatile compared to industry and market?
4151 volatility
4151 Average Weekly Movement6.2%
Pharmaceuticals Industry Average Movement3.7%
Market Average Movement4.1%
10% most volatile stocks in JP Market8.1%
10% least volatile stocks in JP Market2.3%

Stable Share Price: 4151 has not had significant price volatility in the past 3 months.

Volatility Over Time: 4151's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of JP stocks.

About the Company

FoundedEmployeesCEOWebsite
19495,974Masashi Miyamotowww.kyowakirin.com

Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, marketing, and import/export of pharmaceuticals for oncology, nephrology, central nervous system, and immunology therapeutic areas in Japan, the United States, rest of the Americas, Europe, Asia, and internationally. Its products include ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops GRAN /Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson’s disease; and ORKEDIA, an oral calcimimetics agent.

Kyowa Kirin Co., Ltd. Fundamentals Summary

How do Kyowa Kirin's earnings and revenue compare to its market cap?
4151 fundamental statistics
Market capJP¥1.42t
Earnings (TTM)JP¥81.19b
Revenue (TTM)JP¥442.23b

17.3x

P/E Ratio

3.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4151 income statement (TTM)
RevenueJP¥442.23b
Cost of RevenueJP¥111.21b
Gross ProfitJP¥331.03b
Other ExpensesJP¥249.84b
EarningsJP¥81.19b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 07, 2024

Earnings per share (EPS)151.74
Gross Margin74.85%
Net Profit Margin18.36%
Debt/Equity Ratio0%

How did 4151 perform over the long term?

See historical performance and comparison

Dividends

2.2%

Current Dividend Yield

37%

Payout Ratio

Does 4151 pay a reliable dividends?

See 4151 dividend history and benchmarks
When do you need to buy 4151 by to receive an upcoming dividend?
Kyowa Kirin dividend dates
Ex Dividend DateJun 27 2024
Dividend Pay DateSep 02 2024
Days until Ex dividend63 days
Days until Dividend pay date130 days

Does 4151 pay a reliable dividends?

See 4151 dividend history and benchmarks
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.